Zevra Therapeutics Announces Details for Q3 2026 Financial Results CallGlobeNewsWire · 4 days ago
Zevra Therapeutics: Cash Plus A Drug Priced Below Its Rival's DealSeeking Alpha · Oct 15, 2026
Zevra Therapeutics: Miplyffa Validates The Bull Case, Europe Still The Swing FactorSeeking Alpha · Oct 6, 2026
Zevra Therapeutics, Inc. (ZVRA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking Alpha · Sep 15, 2026
Zevra Therapeutics to Present at Upcoming Investor ConferencesGlobeNewsWire · Sep 2, 2026
Zevra Therapeutics to Present New Long-Term Real-World Data on MIPLYFFA® in Niemann-Pick Disease Type C (NPC) at the 2026 SSIEM Annual SymposiumGlobeNewsWire · Aug 25, 2026Zevra Therapeutics, Inc., founded in 2006 and based in Celebration, Florida, is a biopharmaceutical company dedicated to discovering and developing innovative treatments for rare diseases. The company employs its proprietary Ligand Activated Therapy (LAT) technology to create novel prodrug versions of existing FDA-approved medications or to enable new applications for other compounds, primarily addressing serious medical conditions within the United States. Zevra's development pipeline is strategically concentrated on high-unmet-need therapeutic areas, including attention deficit hyperactivity disorder (ADHD), stimulant use disorder, and various rare central nervous system (CNS) conditions, such as idiopathic hypersomnia (IH).
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 5, 2026 | $0.11 | $0.14 | Beat |
| May 6, 2026 | $0.06 | $0.60 | Beat |
| Mar 9, 2026 | $0.05 | $0.21 | Beat |
| Nov 5, 2025 | -$0.02 | -$0.01 | Beat |
| Aug 12, 2025 | $2.19 | $1.21 | Miss |
| May 13, 2025 | -$0.21 | -$0.06 | Beat |